Latest Breaking News On - Associated retinopathies including stargardt - Page 1 : comparemela.com

Conference Call and Webcast Today at 8:30 a.m. ET Announced Positive Preliminary Safety and Efficacy Results from the Phase 1/2 Trial of OCU400 for the Treatment of Retinitis Pigmentosa and Leber. | May 5, 2023

United statesShankar musunuriOcugen incExchange commissionHead of communicationsConference callWebcast todayPositive preliminary safetyEfficacy resultsRetinitis pigmentosaLeber congenital amaurosisOrphan drug designationAssociated retinopathies including stargardtCone rod dystrophyMultiple proposalsFederal funding